Introduction
An hypertensive emergency (HE) is defined as an acute and severe increase in blood pressure (BP) producing target-organ damage that may be lifethreatening. The emergency is a common problem seen in the emergency department at any hospital. 1 The sixth report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC-VI) recommends that any acute and severe elevation in BP, accompanied by evidence of end-organ damage should be considered as an hypertensive emergency where BP must be reduced in less that 1 h. 2 Several oral and intravenous drugs are available for HE treatment. Parenteral agents are the recommended treatment. 2, 3 Oral and sublingual administration of selected drugs, specially when intravenous drugs are not available, may be necessary.
Parenteral agents are not always available in most of the emergency departments in our country, and the personnel working there may not be familiarised of subepicardial ischaemia as seen in the first ECG, both of which disappeared with the drug. Heart rate decreased by 14%. Similarly, all patients in the nifedipine group had significant decreases in BP (190 ± 23/115 ± 7 to 153 ± 26/86 ± 6 mm Hg, P Ͻ 0.005). Their first ECG was normal. Two patients suffered angor pectoris after nifedipine, with subepicardial ischaemia registering in the second ECG. Heart rate increased 11.9% in this group. During the follow-up period, no clinically significant side effects or cases of rebound hypertension were observed in the ISA group, whereas in the nifedipine group, eight patients reported having headaches and four others rebound hypertension. Conclusion: Our results show a favourable effect of ISA in the treatment of HE.
with administering intravenous nitroglycerin or nitroprusside.
Nifedipine has long been used for the oral treatment of hypertensive emergencies. Its effect is characterised by a prompt lowering of BP in these patients, but has disadvantages where this effect may be intense and uncontrolled, producing a high incidence of side effects. 4, 5 Isosorbide dinitrate (ID) is a nitric oxide donor. Its administration in aerosol form in the oral mucosa is followed by a fast initial action. It is effective in the treatment of myocardial ischaemia. 6 Nitric oxide donors have been successfully used as parenteral therapy in HE, in fact both nitroprusside and nitroglycerin release nitric oxide. 3, 7 Therefore isosorbide dinitrate aerosol, a fast-acting nitric oxide donor, may be effective in the treatment of hypertensive emergencies.
The aim of this study is to compare the efficacy of ID aerosol and nidefipine in the treatment of HE.
Materials and methods
Sixty patients admitted to the Ticoman General Hospital emergency department with an hypertensive emergency (mean arterial pressure [MAP] Ͼ130 and evidence of end-organ damage), were randomly divided into two groups of 30 patients each. Group 1 received isosorbide dinitrate aerosol 1.25 mg through the oral mucosa when admitted, and a second dose was given 15 min later when the MAP decreased Ͻ15%. Group 2 received nifedipine 10 mg sublingually as a single dose (the capsule was punctured, its content was squeezed under the patient's tongue, and the capsule was discarded).
We used a formulation of isosorbide dinitrate aerosol available in Mexico for clinical use (Isoket, distributed by Knoll Mexico), and approved by the health authorities (Reg 002M88 SSA). This preparation has a propellent valve (fabricated by Schwarz Pharma, Germany) that provides 1.25 mg of the drug with each application.
Patients with any of the following conditions were excluded from the study: liver failure, chronic renal failure, drug or ethanol abuse, pregnancy.
In both groups, BP was measured using a standard mercurial sphygmomanometer (Tycos, Rochester New York, USA) in triplicate after a period of 5 min resting in the supine position. The personnel measuring each patient's BP was blinded to the patient's group. Readings were taken 2 min apart in the supine position every 5 min for a range of 30 min, and then every 30 min for a total of 6 h. All patients were given an electrocardiogram (ECG) (Burdick EK-10 Siemens, Milton Wisconsin, USA) before and 30 min after the drug was administered.
Response to treatment was defined as a MAP reduction over 15%, with a stable reduction of both systolic BP below 180 mm Hg and diastolic BP below 110 mm Hg.
MAP was estimated using the following formula:
2 (diastolic pressure) + systolic pressure 3
Rebound hypertension was defined as an increase in systolic BP of over 180 mm Hg or diastolic BP over 110 mm Hg, once a stable value was obtained. Individualised antihypertensive drug therapy was started in all patients at the end of the study, 6 h after admission. No other antihypertensive drug was administered in any patient during the study.
All data are presented as mean ± standard deviation values. Statistical analysis was performed using Student's t-test and analysis of variance (ANOVA) for inter-and intragroupal changes; P Ͻ 0.05 was considered statistically significant.
The investigation was performed in accordance with the Helsinki Declaration and was approved by the investigation and Ethic Committees. Informed consent (including nifedipine's risk, available therapeutic options and the risk of delaying treatment) was obtained from all patients (or their relatives if the patient had encephalopathy) before enrolment.
Results
Baseline characteristics for both groups are shown in Table 1 .
Nine (30%) of the patients in group 1 responded with the first application, 21 (70%) required a second dose. Systolic and diastolic values declined from 187 ± 13/121 ± 6.6 mm Hg to 153 ± 15/92.3 ± 7 mm Hg (P Ͻ 0.005). MAP decreased from an average of 136 ± 3 mm Hg to 109.5 ± 4 mm Hg after the drug was administered (19.9% reduction, P Ͻ 0.005). These values were sustained throughout the study ( Figure 1 ). Two patients in this group had angina pectoris and subepicardial ischaemia was detected in the first ECG. After ID was administered, no patient presented with angina pectoris; the second ECG performed was normal for all patients, and showed an average decrease of 14% in heart rate, from 95 ± 15 to 82 ± 14 (P Ͻ 0.005).
In group 2, a significant antihypertensive effect was noted within 10 min after nifedipine was administered. Systolic and diastolic pressures decreased from 190 ± 23/115 ± 7 mm Hg to 153 ± 26/86 ± 6 mm Hg. MAP was 139 ± 10 mm Hg prior to the drug and decreased to 98 ± 13 mm Hg after nifedipine (29.5% reduction, P Ͻ 0.002) (Figure 1 ). All patients in this group had a normal ECG before nifedipine but two of them developed angina pectoris and signs of subepicardial ischaemia were registered in the second ECG after the drug was administered. It also showed an average increase of 11.9% in heart rate, from 81 ± 20 to 91 ± 23 (P Ͻ 0.0025).
After treatment with ID, no clinically significant side effect was recorded. Cases of severe hypotension or rebound hypertension were not observed, whereas eight patients in the nifedipine group reported having headaches and four had an episode of rebound hypertension that was treated with rest.
Discussion
In this study, we have shown that oral isosorbide aerosol is as effective as sublingual nifedipine in the treatment of hypertensive emergencies, is fast-acting causing a prompt and consistent fall in BP. Even when both agents decreased BP to the same extent, nifedipine produced a precipitous fall in BP, while ID aerosol produced a more gradual decline in those values (Figure 1 ). However this is a not-blinded, relatively small study, so statistical evaluation of safety is hard to fulfill.
ID releases nitric oxide-a potent vasodilator-in the vascular endothelium. The entire process takes approximately 7 min, 6 a reason for which the second dose was administered 15 min after the first one when necessary.
Nitrate's use is typically accompanied by reflex tachycardia, 6 ,7 but we found a significant reduction in heart rate following the administration of isosorbide. Although no explanation is currently available for this fact, similar heart rate reductions have been seen when treatment of HE are done using intravenous nitroglycerin. 8 It is interesting to note the absence of side effects when using isosorbide. This is specially true about headaches and rebound hypertension, because both are common with other non-parenteral drugs. This makes an ID aerosol a well-tolerated alternative for the treatment of hypertensive emergencies. Whether or not an ID aerosol is as effective and safe as intravenous agents in the treatment of HE, will require further investigation.
The haemodynamic changes induced by nitrates in the coronary circulation increase the oxigenated blood flow to the heart. These changes as well as the decrease of myocardial oxygen demand secondary to heart rate reduction, may explain relief of angina pectoris which some patients experience while receiving isosorbide dinitrate. 7 Nifedipine induces abrupt and large falls in BP, and may reduce coronary blood flow (dependent on diastolic pressure), occasionally with serious consequences such as acute myocardial infarction. 9 This phenomenon is secondary to abruptly high plasma levels of the drug and is only described with this preparation of nifedipine. This does not occur with the extended release preparation. 10 Cerebral hypoperfusion has also been described with fast-acting nifedipine, with the consequent risk of neurological damage. 11 After nifedipine was administered, two patients suffered myocardial ischaemia. This could have been due to the great MAP reduction that exceeded 25%. With MAP values less than 100 mm Hg, a reduction in coronary blood flow is expected. 1, 3 In addition, the rapid fall in BP prevents the autoregulation of coronary blood flow. Also, the compensatory increase in heart rate of those patients increases myocardial oxygen requirements and causes the onset of ischaemia. It is important to bear all this in mind when treating HE in high risk subjects with ischaemic heart disease, or when ischaemia appears together with raises in BP, in which case other drugs should be used. Headaches and episodes of rebound hypertension (following an excessive catecholamine release) are usually noted when nifedipine is given sublingually, 1,11 but in our study their frequency appears to be lower than that reported in other studies. 1 In conclusion, in this study ID aerosol was effective and well tolerated for the treatment of HE. It seems to be safer than sublingual nifedipine and a good choice for non-parenteral drug therapy of hypertensive emergencies when intravenous agents are unavailable. This formulation of isosorbide dinitrate reduces BP and relieves myocardial ischaemia. It may be a good alternative for patients with both pathologies.
The gradual fall in BP and the convenient management of ID in aerosol favours its use by those physicians who are not familiarised with the use of intravenous agents as nitroprusside.
